Halozyme Thrp Stock Price, News & Analysis

Halozyme (NASDAQ: HALO) has announced a definitive agreement to acquire Elektrofi for $750 million upfront plus up to $150 million in milestone payments. The acquisition centers on Elektrofi's breakthrough Hypercon™ technology, enabling biologic formulations with 400-500 mg/ml concentrations - up to 5 times higher than current standards.

The strategic acquisition expands Halozyme's drug delivery capabilities with long-term IP protection into the 2040s. Two of Elektrofi's partners are expected to begin clinical development of Hypercon™ formulated products by end of 2026, with royalty revenue projected to start in 2030. The transaction is expected to close in Q4 2025 and will be less than 5% dilutive to Non-GAAP EPS over medium-term.

Halozyme reaffirmed its 2025 guidance with total revenue of $1,275-$1,355 million and royalty revenue of $825-$860 million.

Halozyme Therapeutics (NASDAQ: HALO) announced its participation in three upcoming investor conferences in September 2025. CEO Dr. Helen Torley and VP of Investor Relations Tram Bui will represent the company.

The schedule includes presentations at the Wells Fargo Healthcare Conference in Boston on September 4, the Morgan Stanley Global Healthcare Conference in New York on September 8, and the H.C. Wainwright Global Investment Conference in New York on September 9. Live audio webcasts will be available on Halozyme's website with 90-day replay access.

Halozyme (NASDAQ: HALO) reported exceptional Q2 2025 results with total revenue increasing 41% YOY to $326 million and royalty revenue growing 65% YOY to $206 million. Net income surged 77% YOY to $165 million, while adjusted EBITDA rose 65% YOY to $226 million.

The company raised its 2025 guidance, projecting total revenue of $1,275-$1,355 million (26-33% YOY growth) and adjusted EBITDA of $865-$915 million (37-45% YOY growth). Growth was driven by three blockbuster therapies: DARZALEX SC, Phesgo, and VYVGART Hytrulo.

Halozyme announced its third $250 million share repurchase tranche under the $750 million authorized plan, completing $303 million in share repurchases during Q2 2025.

Halozyme Therapeutics (NASDAQ: HALO) announced that Janssen-Cilag received European Commission approval for DARZALEX Faspro®, co-formulated with Halozyme's ENHANZE® technology, for treating high-risk smouldering multiple myeloma (SMM) in adult patients.

This approval marks a significant shift from the current "Watch and Wait" standard of care, enabling early intervention in SMM patients before disease progression. The approval is based on the Phase 3 AQUILA study evaluating fixed-duration monotherapy daratumumab SC versus active monitoring in high-risk SMM patients.

Halozyme Therapeutics (NASDAQ: HALO) has scheduled the release of its second quarter 2025 financial and operating results for Tuesday, August 5, 2025, after market close. The company will host a conference call the same day at 1:30 p.m. PT/4:30 p.m. ET to discuss the results.

Investors can access the conference call through pre-registration and join the live webcast through Halozyme's investor relations website. A replay will also be available on the corporate website.

Halozyme Therapeutics (NASDAQ: HALO) has announced its addition to the U.S. large-cap Russell 1000® Index, effective after market close on June 27th, 2025, as part of FTSE Russell's annual index reconstitution. The Russell 1000® Index comprises approximately 1,000 of the largest U.S. securities based on market capitalization and serves as a key benchmark for large-cap stock performance.

According to CEO Dr. Helen Torley, this inclusion reflects the company's leadership in rapid large-volume subcutaneous drug delivery and their track record of durable top-and-bottom line growth. The membership in the Russell 1000® Index will remain in place for one year.

Halozyme Therapeutics announced that argenx received European Commission approval for VYVGART with ENHANZE for treating chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. The subcutaneous injection, available as a vial or prefilled syringe, is approved for patients previously treated with corticosteroids or immunoglobulins. VYVGART is notable as the first targeted IgG Fc-antibody fragment for CIDP and represents the first new treatment mechanism in over 30 years. The approval, based on the ADHERE clinical trial results, covers all 27 EU Member States plus Iceland, Norway, and Liechtenstein. This development marks a significant milestone in Halozyme's partnership with argenx and supports the company's growth strategy through expanded European market access.

Halozyme Therapeutics (NASDAQ: HALO) has announced its upcoming participation in two major investor conferences. The company's CEO, Dr. Helen Torley, will attend the Benchmark 2025 Healthcare House Call Virtual Conference on May 29, 2025, for one-on-one meetings. Additionally, she will participate in a fireside chat and investor meetings at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on June 9, 2025, at 7:00 AM PT / 10:00 AM ET.

The presentation at the Goldman Sachs conference will be available via live audio webcast in the Investor Relations section of Halozyme's website, with replays accessible for 90 days after the event.

Halozyme Therapeutics (NASDAQ: HALO) announced that Bristol Myers Squibb has received European Commission approval for a subcutaneous formulation of Opdivo® (nivolumab) developed with Halozyme's ENHANZE® technology. The approval covers multiple adult solid tumor indications and makes Opdivo® the first and only PD-1 inhibitor approved for subcutaneous use in the European Union.

The new formulation allows for a 3-to-5-minute subcutaneous injection, offering a more convenient alternative to traditional administration methods. The approval is supported by the Phase 3 CheckMate -67T trial and is valid across all 27 EU member states, plus Iceland, Liechtenstein and Norway. This follows the U.S. FDA approval of Opdivo Qvantig™ in December 2024.